Can-fite Biopharma vs Cardiff Oncology
Cardiff Oncology is the larger business, with $593,000 of revenue in fiscal 2025 against $405,000 for Can-fite Biopharma (1.5 times as much). Cardiff Oncology grew faster (-13.2% against -39.9%). Can-fite Biopharma kept more of each dollar of sales as profit: a net margin of -2426.7% against -7732.0%.
| Latest fiscal year | Can-fite BiopharmaCANF, 2025 | Cardiff OncologyCRDF, 2025 |
|---|---|---|
| Revenue | $405,000 | $593,000 |
| Revenue growth | -39.9% | -13.2% |
| Net income | −$9.8m | −$45.9m |
| Operating margin | — | — |
| Net margin | -2426.7% | -7732.0% |
| Return on equity | -178.2% | -71.5% |
| Free cash flow | −$9.0m | −$38.0m |
| Cash | $5.5m | $17.5m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 31 |
| Market value | $2.1m | $58.6m |
| Price vs our value range | — | — |
| Moat score | — | 5 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 4 buys, 0 sales |